US2002031563A1PendingUtilityA1

Method of inhibiting tumor necrosis factor

43
Priority: Sep 30, 1992Filed: Jan 10, 2001Published: Mar 14, 2002
Est. expirySep 30, 2012(expired)· nominal 20-yr term from priority
Inventors:Thomas Hodge
A61K 31/704A61K 31/09A61K 31/22A61K 31/34A61K 31/365A61K 31/70A61K 35/28A61K 36/254
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a method of inhibiting TNF comprising administering a TNF-inhibiting amount of an extract of Eleutherococcus senticosus maxim to a subject. Also, the present invention provides a method inhibiting TNF in a cell comprising administering to the cell a TNF inhibiting amount of an extract from Eleutherococcus senticosus maxim . Finally, the invention provides a method of treating a TNF mediated disorder in a subject, comprising administering a therapeutic amount of an extract of Eleutherococcus senticosus maxim to the subject.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of inhibiting tumor necrosis factor (TNF) in a subject comprising administering to the subject a TNF inhibiting amount of an extract from  Eleutherococcus senticosus maxim.    
     
     
         2 . The method of  claim 1 , wherein the subject is a human.  
     
     
         3 . The method of  claim 1 , wherein the TNF comprises TNF-α.  
     
     
         4 . The method of  claim 1 , wherein the TNF comprises TNF-β 
     
     
         5 . The method of  claim 1 , wherein the TNF inhibiting amount is from about 1:300 dilution to about 1:600 dilution.  
     
     
         6 . The method of  claim 1 , wherein the TNF inhibiting amount is about a 1:300 dilution.  
     
     
         7 . The method of  claim 1 , wherein the extract is CM-4.  
     
     
         8 . A method inhibiting TNF in a cell comprising administering to the cell a TNF inhibiting amount of an extract from  Eleutherococcus senticosus maxim.    
     
     
         9 . The method of  claim 8 , wherein the TNF comprises TNF-α.  
     
     
         10 . The method of  claim 8 , wherein the TNF comprises TNF-β.  
     
     
         11 . The method of  claim 8 , wherein the TNF inhibiting amount is from about 1:300 dilution to about 1:600 dilution.  
     
     
         12 . The method of  claim 8 , wherein the TNF inhibiting amount is about a 1:300 dilution.  
     
     
         13 . The method of  claim 8 , wherein the extract is CM-4.  
     
     
         14 . A method of treating a TNF mediated disorder in a subject, comprising administering a therapeutic amount of an extract of  Eleutherococcus senticosus maxim  to the subject.  
     
     
         15 . The method of  claim 14 , wherein the TNF comprises TNF-α.  
     
     
         16 . The method of  claim 14 , wherein the TNF comprises TNF-β.  
     
     
         17 . The method of  claim 14 , wherein the TNF inhibiting amount is from about 1:300 dilution to about 1:600 dilution.  
     
     
         18 . The method of  claim 14 , wherein the TNF inhibiting amount is about a 1:300 dilution.  
     
     
         19 . The method of  claim 14 , wherein the TNF mediated disorder is selected from the group consisting of toxic shock, cancer and chronic diarrhea.  
     
     
         20 . The method of  claim 14 , wherein the extract is CM-4.  
     
     
         21 . The method of  claim 14 , wherein the subject is a human.

Join the waitlist — get patent alerts

Track US2002031563A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.